Driehaus Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Driehaus Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-131,736	Closed	-$2.3M	–	510
2015 Q1	$2.3M	Buy	+131,736	New	+$2.7M	0.08%	308
2014 Q3	–	Sell	-33,932	Closed	-$443K	–	522
2014 Q2	$443K	Sell	33,932 -1,233	-4%	-$17.5K	0.01%	515
2014 Q1	$756K	Buy	+35,165	New	+$632K	0.02%	421

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Driehaus Capital Management's ABUS Position: Q2 2015 in Review

Driehaus Capital Management sold out of Arbutus Biopharma (ABUS) in Q2 2015, closing a stake of 131,736 shares — an estimated $2.3M sold.

Driehaus Capital Management first reported a position in ABUS in Q1 2014 and held it in 3 quarters. The position peaked at $2.3M in Q1 2015. 63 funds tracked by Wall St. Rank hold ABUS as of Q2 2015.

Driehaus Capital Management reported no remaining Arbutus Biopharma position as of Q2 2015 after selling out during the quarter.
Driehaus Capital Management sold 131,736 Arbutus Biopharma shares in Q2 2015, an estimated $2.3M.
Driehaus Capital Management first reported a position in Arbutus Biopharma in Q1 2014 and held it in 3 quarters.
Driehaus Capital Management's Arbutus Biopharma position peaked at $2.3M in Q1 2015.
63 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2015.

Based on Driehaus Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.